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Abstract. An overview is provided of the methodologies used in determining the time to steady state for
Phase 1 multiple dose studies. These methods include NOSTASOT (no-statistical-significance-of-trend),
Helmert contrasts, spline (quadratic) regression, effective half life for accumulation, nonlinear mixed
effects modeling, and Bayesian approach using Markov Chain Monte Carlo (MCMC) methods. For each
methodology we describe its advantages and disadvantages. The first two methods do not require any
distributional assumptions for the pharmacokinetic (PK) parameters and are limited to average
assessment of steady state. Also spline regression which provides both average and individual assessment
of time to steady state does not require any distributional assumptions for the PK parameters. On the
other hand, nonlinear mixed effects modeling and Bayesian hierarchical modeling which allow for the
estimation of both population and subject-specific estimates of time to steady state do require
distributional assumptions on PK parameters. The current investigation presents eight case studies for
which the time to steady state was assessed using the above mentioned methodologies. The time to
steady state estimates obtained from nonlinear mixed effects modeling, Bayesian hierarchal approach,
effective half life, and spline regression were generally similar.
KEY WORDS: effective half-life; Helmert contrasts; nonlinear mixed effect modeling; no-statistical-
significance-of-trend; steady state.
INTRODUCTION
If the drug is intended for chronic use, an estimate of the
time it takes for a drug plasma concentration to reach steady
state is required for regulatory labeling. Further, regulatory
guidance for studies conducted in special populations or for
assessingdrug interaction may specify that themeasurements of
interest be obtained when drug concentrations have reached
steady state.
Although regulatory guidances discuss the need to
conduct certain types of studies while drug concentrations
are at steady state, there is limited information on exactly
how to determine that steady state has in fact been reached.
During any dosing interval at steady state, the amount of
the drug lost from the body for a dosage form equals the
amount of the drug introduced into the body from the dosage
form. Quantification of such a situation is practically impos-
sible, because it will take an infinite number of half-lives to
reach steady state. Therefore, as Hauck et al.( 1) character-
ized it, “From a clinical perspective, ninety percent (90%) of
the theoretic steady-state value is often used as a practical
definition, as the difference in response to a 10% difference
in concentration can rarely be assessed”. Throughout this
paper, we will define steady state as being at 90% of the
theoretical steady state value in accordance with Hauck et al.
Chiou (2) and Perrier et al.( 3) deduced steady state
estimates from single dose studies based on certain PK
assumptions. It is quite possible that drugs may or may not
meet these assumptions. As a confirmatory approach, steady
state parameters are routinely estimated from Phase 1
multiple dose studies which provide some real time assurance
that the PK thus obtained represents steady state conditions.
In the present paper, limiting ourselves to the estimation
of time to steady state from Phase 1 multiple dose trial data,
we attempt first to describe the ideas and methods currently
available for estimating the steady state parameters for drugs.
Next, we contrast these methods by examining their param-
eter estimates using eight data sets from Phase 1 multiple-
dose studies in healthy volunteers.
In general methods for determining time to steady state
fall into two broad categories based on the pharmacokinetic
parameter used in the calculations, (1) area under the plasma
concentration-time curve (AUC) or (2) trough concentra-
tions. Within each of these broad categories one may
calculate aggregate and individual times to steady state. In
the current paper, the methods for assessing the time to
steady state are classified based on the parameter used i.e.,
AUC or trough concentrations.
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maganti@merck.com)AUC to Estimate the Time to Steady State
This section considers aggregate and individual methods
for estimating time to steady state based on AUC. In our
Phase 1 multiple dose studies, AUC over each dosing interval
is typically determined on first day and last day of dosing.
Aggregate Assessment using AUC
Equivalence of AUC at two Time Points. When a drug has
reached steady state, the AUC over each dosing interval
should be approximately the same. The AUCs measured over
two (not necessarily consecutive) dosing intervals after the
time at which steady state is thought to have been reached,
are tested for equality using bioequivalence bounds (0.80,
1.25). If the confidence interval lay completely within these
bounds, one could then conclude that steady state was
reached by the dosing interval on which the first AUC was
measured.
Individual Assessment using AUC
Effective Half-Life for Drug Accumulation. The effective
half-life of drug accumulation, calculated for each subject
from AUC determined over two dosing intervals, can be used
to estimate the time to steady state for each subject assuming
the drug displays linear pharmacokinetics. That is, multiple
dose pharmacokinetics must be predictable from single dose
pharmacokinetics (4).
During multiple dose administration of a drug at a
constant dose over intervals of time τ, under the assumption
of linear pharmacokinetics, the ratio of AUCs measured over
any two dosing intervals a and b (b>a) for subject, i, can be
approximated by
AUCbi 0   ðÞ
AUCai 0   ðÞ
¼
1   e  ibi    
1   e  iai  ðÞ
ð1Þ
where ηi is the effective rate of drug accumulation such that
half-life equals ln(2)/ηi and τ is the length of the dosing
interval.
In our multiple dose studies, AUC0−τ for each subject, i,
is typically calculated for first dose (a=1) and for the last dose
(b=last). In this setting, the left side of Eq. 1 becomes the
AUC accumulation ratio. The corresponding value of ηi can
then be solved for iteratively, by substituting values of ηi into
the right side of the equation, until the result equals the
accumulation ratio.
The value of ηi in turn, can be used to estimate the
subject’s fraction of steady state, fssi , attained as follows:
fssi ¼ 1   exp N i    
ð2Þ
for N=1, 2,…, b. The number of dosing intervals needed to
reach 90% of steady state, t0:9i , may be calculated as
t0:9i ¼
2:3
 i
ð3Þ
The proportion of subjects who have reached 90% of
theoretical steady state by a particular dosing interval may
then be summarized for each dose.
For application of this methodology the following
inequality should hold true.
1 < AUCb=AUCa ðÞ < b=a ðÞ ð 4Þ
Trough Concentrations to Estimate Time to Steady State
This section describes the methodologies used to assess
the time to steady state using trough plasma concentrations
obtained from Phase 1 multiple dose studies. The trough
concentration is measured at the end of the dosing interval,
immediately prior to the next dose.
Aggregate Assessment using Trough Concentrations
The two aggregate methods described in this section all
use a hypothesis testing approach to conclude that steady
state has been reached by a particular day.
Stepwise Tests of Linear Trend. Since, at steady state, trough
concentrations are expected to be approximately the same
over any dosing interval, this approach involves an examina-
tion of the concentration curve over time to determine
whether there is a range of time points over which the curve
has “flattened out” after first increasing. The method for
testing whether the curve is flat involves stepwise testing for
linear trend, similar to the NOSTASOT (No-Statistical-
Significance-of-Trend) method of Tukey et al.( 5). The
NOSTASOT method was developed in the context of testing
for progressiveness of response to a drug with increasing
dose; for example, in animal toxicity studies.
One difference between the scenarios described by
Tukey et al.( 5) and our Phase 1 multiple dose studies is
related to the independence of observations. The studies
described in their paper employ separate groups of subjects at
each dose (the “treatment” of interest). In typical multiple
dose studies, trough concentrations are measured at multiple
time points in the same group of subjects. Rather than being
independent, these multiple observations within each subject
are correlated. The correlation can be modeled using the
linear mixed-effect model approach and having a random
effect for subject in the model.
Another difference is that this testing procedure assumes
that the plasma concentration curve is monotonically nonde-
creasing. Misleading results can be obtained if the procedure
is applied to drugs with a nonmonotonic profile (e.g., drug for
which autoinduction occurs).
The application of the NOSTASOT methodology to
trough concentrations involves straight line approximations to
the aggregate plasma concentration curve over specified time
intervals; therefore, the null hypothesis is that there is no
linear trend, i.e., the slope of the regression line equals zero.
The alternative is that there is a linear trend (slope not equal
to zero). The first linear contrast uses the entire range of time
points included in the model. If the contrast is significantly
different from zero at alpha=0.05, a new linear contrast is
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continues, based on contrasts successively excluding the next
earliest time point from the start of the study, until the
contrast is no longer significantly different from zero or until
only three time points remain in the contrast. If the final
contrast is not statistically significant, then the first time point
included in that contrast is considered to be the time point at
which steady state is attained. If the final contrast includes
three time points and is still statistically significant, then
steady state is considered not to have been attained by the
end of the study.
In addition to testing whether each contrast (i.e., slope)
equals zero, a 90% confidence interval for the true slope may
be constructed using the repeated measures ANOVA model.
It should be noted that the above stepwise procedure is a
closed test in the sense of Marcus et al.( 6), due to the
assumption of monotonically nondecreasing mean trough
concentrations. Therefore, no adjustment for the significance
level is needed at each test step; the overall Type 1 error rate
is controlled at 0.05.
Helmert Transform. In Helmert transformation, as discussed
by Chow and Liu (7), the first contrast tested compares the
mean concentration at the first time point to the pooled mean
over all remaining time points. The second contrast compares
the mean at the second time point to the pooled mean over
all remaining time points. Testing continues until the contrast
is not statistically significant. The first time point included in
this last contrast is concluded to be the dosing interval on
which steady state is attained. For example, if there were five
time points included in the ANOVA, then the four contrasts
would have coefficients as shown in Table I.
Individual Assessment using Trough Concentrations. The
following sections discuss three methods for modeling each
subject’s trough concentration–time curve individually.
Spline (Quadratic Plateau) Regression. Quadratic plateau
regression offers another means of estimating an individual’s
time to steady state based on trough plasma concentrations.
This approach uses a segmented model, in which a quadratic
equation Y ¼ A þ Bx þ Cx2   
is assumed to fit the trough
concentrations, up to a certain point x0, after which the data
are assumed to follow a horizontal line. The point x0 is the
time at which the maximum of the quadratic curve occurs
x0 ¼  0:5B=C ðÞ and this “cut-point” x0 is declared to be the
time to steady state.
This method assumes that the curve to be totally flat
from a certain point onward.
Nonlinear Mixed Effects Modeling. The application of non-
linear mixed effects modeling to estimate steady state is
gaining considerable attention as it estimates both population
and subject-specific parameters. Hoffman et al.( 8) presented
a comprehensive review on the usage of nonlinear mixed
effects modeling in assessing the time to steady state. The
authors cover the theoretical background of the methodology
and compared the performance of the nonlinear mixed effects
modeling approach to ANOVA based approaches by means
of simulation. Nonlinear mixed effects modeling allows for
subject-specific as well as population-specific estimates of the
time to steady state for both data-rich and data-sparse
situations.
Assuming a monoexponential mean model for the time
course of the drug plasma trough concentrations, we have the
following expression (9):
ft ij;  i
  
¼ Css i ðÞ 1   e
 2:3tij=t0:9i
  
ð5Þ
f is a scalar function of tij, jth dosing interval for ith subject. θi
is a vector of unknown effects parameters to be estimated.
The intra-individual variation in the plasma trough
concentrations Cij, is modeled as,
Cij ¼ ft ij;  i
  
e"ij ð6Þ
where, ɛij~N(0, σ
2) is the intra-individual random error.
The inter-individual variation in the parameters is
modeled as
 i ¼  e i ð7Þ
where θ is the vector of population mean steady state
parameters [Css and t0.9 (the time at which 90% of the
asymptotic steady state concentration Css, is reached)], γi~N
([0 0]′, ω) is a vector of inter-individual random effects, and ω
is a covariance matrix of γi. Both intra-individual errors (ɛij)
and inter-individual effects (γi) are assumed to be log-
normally distributed.
This methodology assumes one compartment system
with continuous infusion or oral administration with rapid
absorption rate.
Bayesian Approach using MCMC methods. Jordan et al.( 10)
proposed Bayesian hierarchical model using MCMC and
Gibbs sampling for estimating both population and subject
specific times to steady state based on the simple pharmaco-
kinetic model used in Hoffman et al.( 8). The authors used the
following model:
C
i ðÞ
t ¼ C i ðÞ
ss 1   exp
ln 0:1 ðÞ t
ti
0:9
     
e"
i ðÞ
i ð8Þ
t
i ðÞ
0:9 ¼
ln 0:1 ðÞ
 K i ðÞ ð9Þ
Where, C
i ðÞ
t is measured individual concentrations, t
i ðÞ
0:9 is
the time to steady state for an individual i with log-normal
distribution, K is the elimination rate obtained from one com-
partment model, and assumed to be constant over time, and
C
i ðÞ
ss is asymptotic steady-state concentration for each individual
Table I. Coefficients for Four Sequential Linear Contrasts in
Helmert Approach
−1 1/4 1/4 1/4 1/4
0 −1 1/3 1/3 1/3
00 −1 1/2 1/2
00 0 −11
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noted by "
i ðÞ
t   N 0; 
i ðÞ
"
  
,w h e r e 
i ðÞ
" is the individual error
precisiondefinedas  ¼ 1
 
 2 . The joint distribution of ln(C
i ðÞ
ss )
and ln(t
i ðÞ
0:9 ) is given by the following equation (10)
ln C
i ðÞ
ss
  
ln t
i ðÞ
0:9
  
0
@
1
A   N
Cpop
ss
t
pop
0:9
  
;T
  
ð10Þ
T is the precision matrix (4 1 , where Ω is the covariance
matrix of (ln(C
i ðÞ
ss ), ln(t
i ðÞ
0:9 ))', Cpop
ss , t
pop
0:9 , T, and Ω are
population parameters.
q80 ¼ exp ln t
pop
0:9
  
þ z80    t0:9
  
ð11Þ
where, q80 is the 80th percentile of the posterior distribution
of t
i ðÞ
0:9 , z80 is the 80th percentile of the standard normal
distribution and  t0:9 is the population standard deviation. For
discussion on how the priors for the population parameters
and the individual error precision were set, and for further
details on the model, inference and probabilistic consider-
ations refer to Jordan et al.( 10). Using the above model, the
authors computed posterior distribution of the individual
times to steady state and extracted an estimate of time where,
with 90% certainty, at least 80% of the individuals in the
population have attained steady state.
METHODS
In this paper we have applied all of the above discussed
methodologies for estimating steady state (with the exception
of aggregate AUC approach) to eight case studies. The
compounds examined in the current investigation are limited
to those that follow one compartmental pharmacokinetics
with rapid absorption. The study designs and sample sizes are
representative of some of the typical Phase 1 multiple dose
studies in which time to steady state is estimated. Due to
confidentiality reasons the data and conditions of the trials
have not been disclosed.
Each of the studies employed a parallel group design (if
more than one treatment regimen was administered), and
doses were administered once daily. All the doses in the case
studies examined were administered orally. Trough concen-
trations represent the drug concentrations in the blood
samples collected prior to next dosing. AUC(0–24h) was
obtained over first and final dosing intervals. A brief
description of the studies is provided below.
Study 1. Twelve subjects received 25-mg once daily doses
of the study drug. Trough concentrations were
obtained for dosing intervals 1, 2, 3, 4, 5, 6, 7, 8,
9, and 10.
Study 2. Sixteen subjects received 12.5-mg once daily
doses of the study drug. Trough concentrations
were obtained for dosing intervals 1, 4, 5, 6, and 7.
Study 3. Eight subjects received 100-mg once daily doses
of the study drug for 10 days. Trough concen-
trations were obtained for dosing intervals 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, and 11.
Study 4. Thirty subjects received once daily doses of the
study drug. Five different doses, 25-, 50-, 100-,
200-, and 400-mg were administered to five
groups, each group consisting of six subjects.
Both trough concentrations and AUC(0–24h)
values exhibited dose-proportionality, therefore,
all the data were dose-adjusted to 200-mg and
analyzed together. Trough concentrations were
obtained for dosing intervals 2, 3, 5, 7, 9, 11, 13,
14, and 15.
Study 5. Six subjects received 25-mg once daily doses of
the study drug. Trough concentrations were
obtained for dosing intervals 2, 4, 6, 8, 9, and 11.
Study 6. Twenty four subjects received 125-mg once daily
doses of study drug. Trough concentrations were
obtained for dosing intervals 1, 2, 3, 4, 5, 6, 7, 8,
and 9.
Study 7. Twenty five subjects received 100-mg once daily
doses of study drug. Trough concentrations were
obtained for dosing intervals 1, 2, 3, 4, 6, 9, 13,
16, 18, 19, 20, and 21.
Study 8. Twenty four subjects received once daily doses
of the study drug. Four different doses 0.3-, 1.0-,
3.0- and 7.0-mg doses were administered to 4
groups. Each group consisted of 6 subjects. Both
trough concentrations and AUC(0–24h) values
exhibited dose-proportionality, therefore, all the
data were dose-adjusted to 1.0-mg and analyzed
together. Trough concentrations were obtained
for dosing intervals 1, 2, 3, 4, 5, 6, 8, 10, 12, 13,
and 14.
SAS (11) PROC MIXED was used for the NOSTASOT
and Helmert methods, and SAS (11) PROC NLIN was used
for the quadratic modeling. SAS (11) PROC NLMIXED was
used for the non linear mixed effects modeling. In the current
investigation the Gaussian quadrature for approximating the
integral of the likelihood over random effects was utilized. As
discussed previously, the Bayesian analysis was run using
WinBUGS® (12) to estimate steady state parameters. Win-
BUGS® (12), a free downloadable software from the Web,
provides extensive statistical summary with mean, standard
deviation (equivalent to standard error in other methods),
and quantile values. It is commonly used for performing
hierarchical problem-solving using various types of distribu-
tions. The algorithm to solve for effective rate of drug
accumulation was written in SAS (11).
RESULTS
Estimates of time to steady state for these clinical trials
are presented in Table II. In all cases, methods including
Bayesian, nonlinear mixed effects modeling, and spline
regression provided generally similar time to steady state
estimates. Bayesian analysis was effective in providing both
population and individual estimates for all the studies, while
nonlinear mixed effect modeling failed to provide meaningful
individual time to steady state estimates in two studies where
the numbers of subjects were ≤8 (Study 3 and Study 5). In
these studies, the estimate for inter-individual variation in the
parameter t0.9 had extremely poor precision.
Except for Study 2, the time to steady state estimates
determined using the effective half life for accumulation were
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methods. In Study 2, because of the design of the study,
trough concentrations were collected for dosing intervals 1
and 4–7. No data were available for dosing intervals 2 and 3,
therefore, all other methodologies estimated steady state to
have been reached by ~ sixth dose. Also, NOSTASOT could
not estimate the time to steady state because the final
contrast which included the last three time points (dosing
intervals 5, 6, and 7) was still statistically significant.
The mean steady state estimates calculated from qua-
dratic modeling were slightly higher for some studies as
compared to the estimates obtained from Bayesian or
nonlinear mixed effect modeling. This may be attributed to
the fact that the mean is influenced by the extreme values.
From the case studies, it appears that methods that pro-
vide individual estimates of steady state are preferable, as
they allow estimation of both the mean and variance of the
population distribution. In addition, some methods allow esti-
mation of how long it takes to reach any specified percent of
steadystate.Subjectsreachsteadystateatdifferenttimes,there-
fore, aggregate assessment approaches such as NOSTASOT
and Helmert contrasts have limited value. Individual methods
evaluated in this paper included: (1) nonlinear mixed effect
modeling, (2) Bayesian hierarchical modeling, (3) spline
regression (quadratic modeling) and (4) calculating individual
effective half-life of drug accumulation using AUC and
determining time to steady state from that. These methods
will also enable one to calculate confidence intervals for steady
state estimates, fraction of steady state achieved and the
percentage of subjects at 90% of steady state for each study
day. In our limited experience we found in some studies with
smaller number of subjects nonlinear mixed effects modeling
resulted in extremely poor precision for the estimate of the
parameter of interest in terms of inter-individual variability.
If the linearity assumption in AUC is valid, calculating
effective half life of drug accumulation using AUC and
determining time to steady state from that may be used as
primary method of assessing the time to steady state in our
Phase 1 multiple dose trials. As a confirmatory approach,
trough concentrations values may be analyzed, with a
nonlinear mixed effects model or Bayesian hierarchical
modeling. If there is reason to believe that the kinetics of
the compound are not linear, time to steady state can be
assessed using a method that does not require any assump-
tions about the underlying compartmental model (e.g.,
stepwise tests of linear trend in trough concentrations or
spline regression if applicable).
DISCUSSION
Time to steady state can be estimated by using either an
aggregate or individual approach. Aggregate methods yield
one result like, “steady state was achieved by day x”.
Individual methods yield this result for each individual in
the clinical trial, allowing for characterization of the distribu-
tion of time to steady state for the entire population. Because
of the additional information obtained about the range and
Table II. Steady State Estimates for Case Studies
Cases Parameters
Quadratic
Modeling NOSTASOT
Helmert
Contrasts
Effective
Half life
Bayesian
Approach
Non Linear
Mixed Effects Modeling
Study 1, N=12 Css 108.6 (11.53) 2 3 100.7 (12.71) 100.9 (10.78)
t0.9 3.5 (0.43) 2.5 (0.24) 2.5 (0.34) 2.6 (0.27)
Range of t0.9 1.6–6.4 1.5-4.2 1.7-3.6 2.2–3.2
Study 2, N=16 Css 12.4 (1.22) Not achieved 6 12.5 (1.40) 12.3 (1.22)
t0.9 5.9 (0.37) 2.1 (0.12) 5.6 (0.88) 5.6 (0.58)
Range of t0.9 3.3–8.7 1.3–3.1 5.0–6.6 5.1–6.2
Study 3, N=8 Css 97.3 (9.96) 3 4 95.1 (11.67) 93.9 (8.76)
t0.9 1.6 (0.12) 1.2 (0.11)
a 1.4 (0.14) 1.4 (0.08)
Range of t0.9 1.0–2.1 0.7–1.6 1.3–1.5 –
b
Study 4, N=30 Css 2129.3 (129.9) 5 3 2,029.0 (120.00) 2,013.2 (112.30)
t0.9 3.8 (0.42) 3.9 (0.30)
c 2.9 (0.26) 3.1(0.23)
Range of t0.9 1.1–10.3 1.9–7.5 1.5–6.5 1.3–6.4
Study 5, N=6 Css 68.9 (4.79) 4 7 68.6 (6.42) 68.8(4.61)
t0.9 4.4 (0.39) 3.5 (0.37) 3.5 (0.62) 3.7 (0.35)
Range of t0.9 3.3–5.9 2.6–4.7 3.3–4.0 –
b
Study 6, N=24 Css 1297.9 (172.21) 7 6 1,061.0 (126.41) 1,032.4 (114.50)
t0.9 6.2 (0.78) 3.6 (0.37) 4.1(0.42) 4.1 (0.35)
Range of t0.9 2.0–19.2 1.4–10.5 2.5–6.3 2.2–6.1
Study 7, N=25 Css 314.9 (17.57) 6 7 309.9 (18.52) 312.7 (17.98)
t0.9 6.9 (0.43) 3.6 (0.27) 6.1 (0.49) 6.3 (0.53)
Range of t0.9 3.0–12.2 1.3–7.6 2.9–12.1 2.8–20.2
Study 8, N=24 Css 137.6 (4.61) 5 6 133.7 (5.06) 139.2 (4.69)
t0.9 5.6 (0.24) 4.9 (0.22)
c 4.6 (0.22) 4.7 (0.20)
Range of t0.9 4.3–8.1 3.8–7.5 4.0–6.0 3.6–6.5
Mean (standard error) are reported for all the methods except for nonlinear mixed effects and Bayesian hierarchical modeling for which
population estimates are reported.
aAUCb/AUCa <1 for one subject
bInterindividual variation had extremely poor precision
cSome missing data
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generally preferred.
Based on our experience with Phase 1 multiple dose
studies, we listed advantages and disadvantages of various
methodologies evaluated in this paper in estimating the time
to steady state
Using Area under the Curve (AUC) to Estimate the Time
to Steady State
Aggregate assessment using AUC
Advantages
1. Most are familiar with this methodology, as it is a
commonly accepted (bioequivalence) approach
for showing that two AUCs are “the same”
Disadvantages
1. It is formally hypothesized that steady state is
reached by a particular day. If the hypothesis is
not met, there is no further data from which to
deduce when steady state is really achieved.
2. For drugs with a long half-life, the AUCs on two
consecutive dosing intervals might meet the bio-
equivalence criterion, but steady state may not
have been attained, therefore, other confirmatory
approaches should be applied.
3. Not all subjects reach steady state at the same
time, and this method fails to provide inter-
individual variability
4. The method does not utilize the definition of
steady state as the day at which 90% of the
asymptotic concentration is reached.
Individual Assessment using AUC
Advantages
1. An estimate of the time to steady state and
fraction of steady state can be calculated for each
subject.
Disadvantages
1. This approach is applicable to drugs that exhibit
linear pharmacokinetics, i.e., multiple dose PK is
predictable from single dose PK.
2. Effective half-life can only be calculated if the
inequality 1<(AUCb/AUCa)<(b/a) holds true.
3. Computationally more difficult to implement
Using Trough Concentrations to Estimate the Time to Steady
State
Application of the trough concentrations for estimating
steady state can be more economical, timely, and practical as
it is more costly to acquire AUC data (requiring full PK
profiles on two days).
Aggregate Assessment using Trough Concentrations
Stepwise Tests of Linear Trend.
Advantages
1. The approach makes no assumptions about the
underlying PK model.
2. Thedosingintervalatwhichsteadystateisexpected
to be attained does not have to be pre-specified.
Disadvantages
1. Most obvious problem with the procedure is lack
of adequate power. The size of the detectable
slope decreases with increasing sample size, and
with increasing dosing intervals in the contrast.
Thus, during the later part of the study, when the
true slope is getting smaller, the ability to detect
that slope is also reduced and one might conclude
that steady state was attained on a particular day,
because there was inadequate power to detect the
slope at that time point. A study with smaller
number of subjects might conclude that steady
state was attained on an earlier day than a larger
study because the large study would have the
power to detect smaller slopes. It should be
further noted that, because of the decreasing
number of time points included in the contrast,
the power to detect a particular slope decreases
as the stepwise testing progresses. At the same
time, the true slope being estimated is decreasing.
2. The application of bounds on slope which corre-
sponds to the Bioequivalence bounds may not be
appropriate as the slope being estimated is
dependent on the study design, such as number
of time points sampled and length of the study. As
well, the underlying curvature between any two
time points, which the slope approximates, varies
with the elimination rate constant of the drug. In
summation, drugs with a longer half-life have a
more gradual approach to steady state. Therefore,
the slope over a particular time interval will be
smaller for a drug with a longer half-life.
3. Since the procedure is limited only to the dosing
intervals included in the contrasts, it may over or
underestimate time to steady state if trough concen-
trations were not measured in each dosing interval.
4. No measure of between-subject variability is
obtained.
5. This procedure does not guarantee that the
concentration measured on the estimated day on
which steady state is attained is within 90% of the
theoretical steady state concentration
Helmert Transformation.
Advantages
1. An advantage over the stepwise tests of linear
trend is that it may be easier to set clinically
meaningful bounds for this approach than for the
slope test. The usual bioequivalence bounds of
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on the 90% confidence interval for the contrasts.
Disadvantages
1. In order for the testing procedure to be closed,
testing has to stop when the first nonsignificant
contrast is reached. It is possible, however, that
one or more contrasts further on in the study may
be statistically significant.
2. As discussed in the stepwise test of linear trends,
the power associated with the contrasts decreases
as fewer (later) days are included in the contrast.
3. Since the procedure is limited only to the dosing
intervals included in the contrasts, it may over or
underestimate time to steady state if trough
concentrations were not measured in each dosing
interval.
4. No measure of between-subject variability is
obtained.
5. This procedure does not guarantee that the
concentration measured on the estimated day on
which steady state is attained is within 90% of the
theoretical steady state concentration.
Individual Assessment using Trough Concentrations
Spline (Quadratic Plateau) Regression.
Advantages
1. This method may be useful in approximating the
form of a curve that is not adequately modeled by
a monoexponential equation.
2. It does not require any distributional assumptions
on PK parameters.
Disadvantages
1. The curve is assumed to be totally flat from a
certain point onward whereas the true concen-
trations follow some curve.
2. A subject is declared to be “at steady state” on a
particular day without providing information on the
true fraction of steady state attained on that day.
Nonlinear Mixed Effects Modeling.
Advantages
1. This approach could estimate both average and
individual steady state estimates.
2. This approach yields parameter estimates for both
data-rich and data-sparse cases.
3. Model could be extended to subpopulations or
covariates
Disadvantages
1. The model specified here is limited to one
compartment model with continuous infusion, IV
bolus administration or oral administration with
fast absorption.
2. Limited number of samples and highly variable
drugs among individuals may likely cause conver-
gence problems.
Bayesian Approach using MCMC methods.
Advantages
1. This methodology provides both population and
subject specific steady state estimates.
2. Jorden et al.( 10) claim that this approach is
applicable to possibly more complex pharmacoki-
netic relationships.
3. Bayesian framework allows drawing of additional
conclusions by providing certainty about the
steady state estimates.
Disadvantages
1. Requires familiarity with Bayesian methodology.
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